Idiopathic Cd4 Positive T Lymphocytopenia C0206744
A condition characterized by abnormally low CD4 T-cell counts in the blood, not caused by HIV. Patients face higher risks of opportunistic infections and certain cancers. Ongoing medical monitoring and infection prevention strategies are essential components of care.
Key facts at a glance
- ICD-10
- D89.9
- ICD-11
- 3A00.0
- Body system
- immunologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Pneumocystis pneumonia
Generalized symptoms
(immunologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Persistent oral candidiasis
(mucocutaneous)Extensive warts
(integumentary)Systemic lupus erythematosus-like autoimmunity
(immunologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Opportunistic Infection Prophylaxis
Lifelong prophylaxis regimen targeting PCP, toxoplasmosis, and mycobacterial infections appropriate to CD4 nadirs. Treatment regimens adjusted based on individual patient risk profile and CD4 recovery.
Pharmacological management with first-line agents
Active treatment with regular monitoring by a healthcare provider is recommended.
Comprehensive Immunological Monitoring
Serial measurements of CD4+ counts, immunoglobulin levels, and lymphocyte subset analysis to track disease progression and response to interventions.
Additional treatment options
Antiviral Therapy for Specific Infections
Targeted antiviral therapy administered promptly upon detection of viral infections such as HSV, VZV, or CMV. Treatment duration extended compared to immunocompetent hosts.
medicationStress Management and Sleep Optimization
Stress reduction techniques and sleep hygiene optimization to minimize immune suppression from chronic stress. Regular exercise within patient tolerance supports immune function.
lifestyleMacronutrient and Micronutrient Support
High-protein diet with adequate calories to maintain nutritional status. Supplementation with vitamins A, C, E, and B-complex to support cellular immunity and antibody production.
dietaryWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Idiopathic Cd4 Positive T Lymphocytopenia C0206744?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat Idiopathic Cd4 Positive T Lymphocytopenia C0206744. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy